Profiel
Samuel K.
Ackerman is the founder of Pentose Pharmaceuticals, Inc. He currently holds the position of President & Chief Executive Officer at Cyclis Pharmaceuticals, Inc. and Chairman at Vitex Systems, Inc. Previously, he served as Chairman & Chief Executive Officer at V.I.
Technologies, Inc. from 1999 to 2005, Chairman, President & Chief Executive Officer at Panacos Pharmaceuticals, Inc. from 2005 to 2006, and as a Principal at OraVax, Inc. in 1995.
He also worked as a Partner at Ampersand Management LLC.
Actieve functies van Samuel K. Ackerman
| Bedrijven | Functie | Begin |
|---|---|---|
Cyclis Pharmaceuticals, Inc.
Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops small molecule drugs for the treatment of cancer | Algemeen Directeur | - |
Vitex Systems, Inc. | Voorzitter | - |
Eerdere bekende functies van Samuel K. Ackerman
| Bedrijven | Functie | Einde |
|---|---|---|
| PANACOS PHARMACEUTICALS, INC. | Algemeen Directeur | 15-06-2006 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Develops blood products and systems using its proprietary viral inactivation technologies | Voorzitter | 01-08-2005 |
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Develops oral vaccines and non injected antibody products | Corporate Officer/Principal | 31-12-1995 |
Pentose Pharmaceuticals, Inc.
Pentose Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel antiviral products | Oprichter | - |
Ampersand Management LLC
Ampersand Management LLC Investment ManagersFinance Ampersand Management invests in companies located in North America, Europe and APAC with an EBITDA of USD 2 - 40 million and revenues of USD 10 - 200 million. The firm targets companies operating in the fields of contract manufacturing, pharma services, specialty products, laboratory products and laboratory services. It participates in MBOs, corporate divestitures, recapitalization and growth stage capital requirements with an investment size of USD 10 - 200 million. The firm acquires majority and minority interests. | Private Equity Investor | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Develops oral vaccines and non injected antibody products | Health Technology |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Develops blood products and systems using its proprietary viral inactivation technologies | Health Technology |
Vitex Systems, Inc. | |
Ampersand Management LLC
Ampersand Management LLC Investment ManagersFinance Ampersand Management invests in companies located in North America, Europe and APAC with an EBITDA of USD 2 - 40 million and revenues of USD 10 - 200 million. The firm targets companies operating in the fields of contract manufacturing, pharma services, specialty products, laboratory products and laboratory services. It participates in MBOs, corporate divestitures, recapitalization and growth stage capital requirements with an investment size of USD 10 - 200 million. The firm acquires majority and minority interests. | Finance |
Pentose Pharmaceuticals, Inc.
Pentose Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel antiviral products | Health Technology |
Cyclis Pharmaceuticals, Inc.
Cyclis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops small molecule drugs for the treatment of cancer | Health Technology |
Panacos Pharmaceuticals, Inc.
Panacos Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small molecule drugs | Health Technology |
















